NASDAQ:DMTK DermTech (DMTK) Stock Forecast, Price & News $1.65 -0.05 (-2.94%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.62▼$1.6950-Day Range$1.64▼$3.7952-Week Range$1.55▼$6.44Volume125,706 shsAverage Volume472,946 shsMarket Capitalization$55.61 millionP/E RatioN/ADividend YieldN/APrice Target$6.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media DermTech MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside283.8% Upside$6.33 Price TargetShort InterestBearish16.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 5 Articles This WeekInsider TradingSelling Shares$42,134 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.56) to ($2.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsMedical Sector789th out of 965 stocksMedical Laboratories Industry20th out of 23 stocks 3.4 Analyst's Opinion Consensus RatingDermTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, DermTech has a forecasted upside of 283.8% from its current price of $1.65.Amount of Analyst CoverageDermTech has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.34% of the float of DermTech has been sold short.Short Interest Ratio / Days to CoverDermTech has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in DermTech has recently increased by 10.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDermTech does not currently pay a dividend.Dividend GrowthDermTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMTK. Previous Next 3.1 News and Social Media Coverage News SentimentDermTech has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for DermTech this week, compared to 1 article on an average week.Search Interest5 people have searched for DMTK on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added DermTech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DermTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,134.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of DermTech is held by insiders.Percentage Held by InstitutionsOnly 27.81% of the stock of DermTech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for DermTech are expected to grow in the coming year, from ($3.56) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DermTech is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DermTech is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermTech has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DermTech (NASDAQ:DMTK) StockDermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Read More DMTK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMTK Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comDermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)September 19, 2023 | uk.style.yahoo.comOne penny stock I’m having second thoughts aboutSeptember 23, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 19, 2023 | finance.yahoo.comDermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)September 18, 2023 | technews.tmcnet.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of DermTech, Inc. (DMTK) on Behalf of InvestorsSeptember 18, 2023 | stockhouse.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of DermTech, Inc. (DMTK) on Behalf of InvestorsSeptember 15, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Announces Investigation of DermTech, Inc. (DMTK) on Behalf of InvestorsSeptember 13, 2023 | finance.yahoo.comInsider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 SharesSeptember 23, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 11, 2023 | finance.yahoo.comDermTech Appoints Mark Aguillard as Chief Commercial OfficerAugust 9, 2023 | finance.yahoo.comDermTech (NASDAQ:DMTK) Will Have To Spend Its Cash WiselyAugust 8, 2023 | msn.comBTIG Maintains DermTech (DMTK) Buy RecommendationAugust 3, 2023 | finance.yahoo.comDermTech Reports Second-Quarter 2023 Financial ResultsAugust 3, 2023 | markets.businessinsider.comDermTech International Registered earnings: here's what Wall Street expectsJuly 31, 2023 | markets.businessinsider.comDermTech (DMTK) Gets a Buy from Craig-HallumJuly 19, 2023 | finance.yahoo.comDermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)July 17, 2023 | finance.yahoo.comDermTech Announces Release Date for Second-Quarter 2023 Financial ResultsJuly 13, 2023 | finance.yahoo.comDermTech, Inc. (NASDAQ:DMTK) surges 21%; retail investors who own 59% shares profited along with institutionsJuly 12, 2023 | finance.yahoo.comDermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)July 7, 2023 | msn.comSan Diego’s DermTech trims staff to conserve cash as it pushes scalpel-free diagnostic test for melanomaJune 29, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: DermTech (DMTK) and NeuroPace (NPCE)June 29, 2023 | msn.comWhy DermTech Shares Are Rising TodayJune 29, 2023 | msn.comDMTK Surges after Restructuring ProgramJune 28, 2023 | msn.comDermTech announces restructuring to focus on its Melanoma Test, lays off 15% of workforceJune 28, 2023 | finance.yahoo.comDermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline OperationsJune 14, 2023 | finance.yahoo.comECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)June 9, 2023 | msn.comDermTech stock surges after it announces contract with Hawaii Blues plan for melanoma testSee More Headlines Receive DMTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter. Email Address DMTK Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DMTK CUSIPN/A CIK1651944 Webwww.dermtech.com Phone(858) 450-4222FaxN/AEmployees278Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.33 High Stock Price Forecast$8.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+283.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,680,000.00 Net Margins-853.02% Pretax Margin-853.02% Return on Equity-99.14% Return on Assets-65.52% Debt Debt-to-Equity RatioN/A Current Ratio5.85 Quick Ratio5.77 Sales & Book Value Annual Sales$14.52 million Price / Sales3.83 Cash FlowN/A Price / Cash FlowN/A Book Value$4.38 per share Price / Book0.38Miscellaneous Outstanding Shares33,700,000Free Float31,981,000Market Cap$55.61 million OptionableNot Optionable Beta2.22 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Kevin Sun M.B.A. (Age 45)CFO, Treasurer & Sec. Comp: $461.92kMs. Claudia Ibarra (Age 61)Chief Operating Officer Comp: $414.09kMr. Ray Akhavan Esq. (Age 54)J.D., Gen. Counsel Comp: $413.06kMr. Bret Christensen (Age 52)Pres, CEO & Director Mr. William W. ZondlerChief Information OfficerMr. Steve E. KunszaboSr. Director of Investor RelationsMs. Jennifer EilembergChief Compliance OfficerMr. Ray BassiVP of SalesDr. Burkhard Jansen M.D. (Age 57)Chief Medical Affairs Officer Mr. Daniel VisageSr. VP of Payer AccessMore ExecutivesKey CompetitorsSera PrognosticsNASDAQ:SERAPersonalisNASDAQ:PSNLTriSalus Life SciencesNASDAQ:TLSIEnzo BiochemNYSE:ENZMDxHealthNASDAQ:MDXHView All CompetitorsInsiders & InstitutionsKevin M SunSold 436 sharesTotal: $824.04 ($1.89/share)Claudia IbarraSold 322 sharesTotal: $608.58 ($1.89/share)Kevin M SunSold 9,180 sharesTotal: $17,717.40 ($1.93/share)Claudia IbarraSold 7,378 sharesTotal: $14,239.54 ($1.93/share)Ramin AkhavanSold 4,531 sharesTotal: $8,744.83 ($1.93/share)View All Insider TransactionsView All Institutional Transactions DMTK Stock - Frequently Asked Questions Should I buy or sell DermTech stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DMTK shares. View DMTK analyst ratings or view top-rated stocks. What is DermTech's stock price forecast for 2023? 4 brokers have issued twelve-month price targets for DermTech's stock. Their DMTK share price forecasts range from $5.00 to $8.00. On average, they expect the company's share price to reach $6.33 in the next year. This suggests a possible upside of 283.8% from the stock's current price. View analysts price targets for DMTK or view top-rated stocks among Wall Street analysts. How have DMTK shares performed in 2023? DermTech's stock was trading at $1.77 at the beginning of the year. Since then, DMTK stock has decreased by 6.8% and is now trading at $1.65. View the best growth stocks for 2023 here. When is DermTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our DMTK earnings forecast. How were DermTech's earnings last quarter? DermTech, Inc. (NASDAQ:DMTK) announced its earnings results on Thursday, August, 3rd. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.95) by $0.04. The company earned $3.98 million during the quarter, compared to the consensus estimate of $3.55 million. DermTech had a negative trailing twelve-month return on equity of 99.14% and a negative net margin of 853.02%. What other stocks do shareholders of DermTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH). What is DermTech's stock symbol? DermTech trades on the NASDAQ under the ticker symbol "DMTK." Who are DermTech's major shareholders? DermTech's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.31%), Triatomic Management LP (1.19%), Epiq Partners LLC (0.90%), Geode Capital Management LLC (0.77%), King Luther Capital Management Corp (0.61%) and Woodmont Investment Counsel LLC (0.38%). Insiders that own company stock include Burkhard Jansen, Claudia Ibarra, Enrico Picozza, Herm Rosenman, John Dobak, Kevin M Sun, Kevin M Sun, Matthew L Posard, Mutual Insurance Co Donegal, Ramin Akhavan, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood. View institutional ownership trends. How do I buy shares of DermTech? Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DermTech's stock price today? One share of DMTK stock can currently be purchased for approximately $1.65. How much money does DermTech make? DermTech (NASDAQ:DMTK) has a market capitalization of $55.61 million and generates $14.52 million in revenue each year. The company earns $-116,680,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. How many employees does DermTech have? The company employs 278 workers across the globe. How can I contact DermTech? DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The official website for the company is www.dermtech.com. The company can be reached via phone at (858) 450-4222 or via email at investorrelations@dermtech.com. This page (NASDAQ:DMTK) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DermTech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.